Epilepsy and cognitive impairments in alzheimer disease

Archives of Neurology

Volumn 66, Issue 4, 2009, Pages 435-440

  Palop, Jorge J ^a,b   Mucke, Lennart ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ANTICONVULSIVE AGENT; APOLIPOPROTEIN E4; PICROTOXIN; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DEMENTIA; DRUG INHIBITION; ENZYME ACTIVITY; EPILEPSY; HUMAN; LEARNING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPATIAL MEMORY; AMNESIA; ANIMAL; BRAIN; DENTATE GYRUS; DISEASE MODEL; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; GENETICS; HETEROZYGOTE DETECTION; HIPPOCAMPUS; METABOLISM; MOUSE; NERVE CELL INHIBITION; NERVE CELL NETWORK; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMNESIA; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEIN E4; BRAIN; COGNITION DISORDERS; DENTATE GYRUS; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; GABA ANTAGONISTS; HETEROZYGOTE DETECTION; HIPPOCAMPUS; HUMANS; MICE; MICE, TRANSGENIC; NERVE NET; NEURAL INHIBITION; PICROTOXIN; SYNAPTIC TRANSMISSION; TAU PROTEINS;

EID: 65249091454     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.15     Document Type: Review

References (49)

1. Snider BJ, Norton J, Coats MA, et al. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol. 2005;62(12):1821-1830.
2. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006;47(5):867-872.
3. Cabrejo L, Guyant-Maréchal L, Laquerriére A, et al. Phenotype associated with APP duplication in five families. Brain. 2006;129(pt 11):2966-2976.
4. Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55(5):697-711.
5. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid p-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750-754.
6. delpolyi AR, Rankin KP, Mucke L, Miller BL, Gorno-Tempini ML. Spatial cognition and the human navigation network in AD and MCI. Neurology. 2007;69 (10):986-997.
7. Deipolyi AR, Fang S, Palop JJ, Yu G-Q, Wang X, Mucke L. Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging. 2008;29(2):253-266.
8. Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999; 96(6):3228-3233.
9. Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999; 2(3):271-276.
10. Palop JJ, Jones B, Kekonius L, et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A. 2003;100(16):9572-9577.
11. Kobayashi DT, Chen KS. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 2005;4(3):173-196.
12. Palop JJ, Chin J, Bien-Ly N, et al. Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J Neurosci. 2005;25(42):9686-9693.
13. Chin J, Palop JJ, Puoliväli J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005; 25(42):9694-9703.
14. Cheng IH, Scearce-Levie K, Legleiter J, et al. Accelerating amyloid-β fibrilliza- tion reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282(33):23818-23828.
15. Meilandt WJ, Yu G-Q, Chin J, et al. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2008;28(19):5007-5017.
16. Janus C, Westaway D. Transgenic mouse models of Alzheimer's disease. Physiol Behav. 2001;73(5):873-886.
17. Götz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9(7):532-544.
18. Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and Alzheimer's disease. Nature. 1997;389(6651):603-606.
19. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factorand therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103(15):5644-5651.
20. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293(5534): 1487-1491.
21. Masliah E, Rockenstein E, Veinbergs I, et al. β-Amyloid peptides enhance α- synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. ProcNatlAcadSciUSA. 2001; 98(21):12245-12250.
22. Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443(7113):768-773.
23. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535-539.
24. Kamenetz F,TomitaT, Hsieh H, et al. APP processing and synaptic function. Neuron. 2003;37(6):925-937.
25. Hsieh H, Boehm J, Sato C,et al. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron. 2006;52(5):831-843.
26. Shankar GM, Bloodgood BL,Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27(11):2866-2875.
27. Chin J, Ling H-P, Comery T, et al. Chronic imbalance in neuronal activity and compensatory plasticity are associated with cognitive impairment in Tg2576 and PS1/APP mouse models of Alzheimer's disease. Presented at: the International Conference on Alzheimer's Disease 2008; July 27, 2008; Chicago, IL.
28. Tanila J, Minkeviciene R, Dobszay MB, et al. Fibrillar beta-amyloid associates with epileptic seizures in APPswe/PS1de9 mice and changes excitability in cortical and hippocampal neurons. Presented at: the Society for Neuroscience Annual Meeting 2008; Nov 18, 2008; Washington, DC.
29. Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 1986;36(9):1226-1230.
30. Romanelli MF, Morris JC, Ashkin K, Coben LA. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol. 1990;47(8):847-850.
31. Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003;20(11):791-803.
32. Mendez MF, Catanzaro P, Doss RC, ARguello R, Frey WH II. Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol. 1994;7 (4):230-233.
33. Volicer L, Smith S, Volicer BJ. Effect of seizures on progression of dementia of the Alzheimer type. Dementia. 1995;6(5):258-263.
34. The Alzheimer disease and frontotemporal dementia mutation database. Flanders Interuniversity Institute for Biotechnology Department of Molecular Genetics Web site. http://www.molgen.ua.ac.be. Accessed September 6, 2008.
35. LarnerAJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease as-sociated with mutations of the presenilin-1 gene. J Neurol. 2006;253(2):139-158.
36. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol. 1989;46(8):849-853.
37. Ponomareva NV, Korovaitseva GI, Rogaev EI. EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiol Aging. 2008;29(6):819-827.
38. Ponomareva NV, Selesneva ND, Jarikov GA. EEG alterations in subjects at high familial risk for Alzheimer's disease. Neuropsychobiology. 2003;48(3):152-159.
39. Busch RM, Lineweaver TT, Naugle RI, et al. ApoE-epsilon4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. Neurology. 2007;68(6):409-414.
40. Bradshaw J, Saling M, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry. 2004;75(3):382-387.
41. Rabinowicz AL, Starkstein SE, Leiguarda RC, Coleman AE. Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord. 2000;14(4):231-233.
42. Sinforiani E, Manni R, Bernasconi L, Banchieri LM, Zucchella C. Memory disturbances and temporal lobe epilepsy simulating Alzheimer's disease: a case report. Funct Neurol. 2003;18(1):39-41.
43. Yoshiike Y, KimuraT, Yamashita S, etal. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE. 2008;3(8):e3029.
44. Fernandez F, Morishita W, Zuniga E, et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. NatNeurosci. 2007;10(4):411-413.
45. Del Vecchio RA, Gold LH, Novick SJ, Wong G, Hyde LA. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett. 2004;367 (2):164-167.
46. Palop JJ,Thwin MT, Ho K, et al. Alterations in voltage-gated sodium channels of transgenic mouse models of Alzheimer's disease: implications for Aβ -induced network dysfunction. Presented at: the International Conference of Alzheimer's Disease 2008; July 27, 2008; Chicago, IL.
47. Herrmann N, Lanctot KL, Rothenburg LS, Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;23(2):116-119.
48. French JA. Refractory epilepsy: clinical overview. Epilepsia. 2007;48(suppl 1):3-7.
49. Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain. 2006; 129(Pt5):1281-1292.